Dexcom Secures Access To Dexcom ONE Sensor For 100,000 Type 2 Diabetes Patients In France; French Government Offers Full National Reimbursement For CGM Technology
Portfolio Pulse from Benzinga Newsdesk
Dexcom has secured access to its Dexcom ONE sensor for 100,000 Type 2 diabetes patients in France, with the French government offering full national reimbursement for the CGM technology.
June 04, 2024 | 2:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Dexcom has secured access to its Dexcom ONE sensor for 100,000 Type 2 diabetes patients in France, with the French government offering full national reimbursement for the CGM technology.
The full national reimbursement by the French government for Dexcom's CGM technology is likely to significantly boost Dexcom's revenues and market penetration in France, positively impacting its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Dexcom's access to the French market with full national reimbursement for its CGM technology may positively impact the broader French healthcare sector, which is represented by the iShares MSCI France ETF (EWQ).
The reimbursement decision for Dexcom's CGM technology could have a positive ripple effect on the French healthcare sector, potentially benefiting the iShares MSCI France ETF (EWQ) in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50